← Human Trials & Peer-Reviewed Studies

Breast stimulation vs low dose oxytocin for labor augmentation in women with a previous cesarean delivery, a randomized controlled trial

Plain-language guide to PMID 40054666 (2025): randomized controlled trial study of Oxytocin.

Key Facts

PMID
40054666
Journal
American journal of obstetrics & gynecology MFM
Year
2025
Study type
Randomized Controlled Trial
Authors
Abu Shqara R et al. (7 authors)
DOI
10.1016/j.ajogmf.2025.101658

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial paper looks at Oxytocin.

In a cohort of patients with one previous CD, the researchers aimed to compare maternal and neonatal outcomes according to the method of labor augmentation; breast stimulation or intravenous oxytocin.

Why It Was Studied

Oxytocin and breast stimulation are methods used for labor augmentation in women with a previous cesarean delivery (CD).

The optimal method of labor augmentation for women with a prior CD has not been established.

Who Took Part

By PubMed's age tags, the people studied were adults, women only.

The participants had one previous CD and a cervical dilatation of 2 to 6 cm, had inadequate uterine contractions, defined as less than 3 per 10 minutes, and were candidates for labor augmentation.

Both augmentation treatments were continued for a maximum of 12 hours.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Oxytocin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

This randomized controlled trial (RCT) was conducted at a single, tertiary, university-affiliated hospital.

An intrauterine pressure catheter was inserted.

If active labor did not occur within 12 hours, the intervention was deemed a failure.

An intention-to-treat analysis was performed.

The co-primary outcomes were the time from augmentation to delivery, and uterine contraction intensity as measured by Montevideo units (MVU).

What Was Measured

Secondary outcomes included intervention failure, meconium-stained amniotic fluid, vaginal delivery after cesarean section, uterine rupture, infectious outcomes, postpartum hemorrhage, and maternal hospitalization length.

The subject headings attached to it are Oxytocin, Oxytocics, Vaginal Birth after Cesarean, Labor, Induced, Uterine Contraction, Pregnancy Outcome and Cesarean Section.

The authors tagged it with the keywords Montevideo, oxytocin augmentation, trial of birth after cesarean, uterine contractions and uterine rupture.

What This Means in Plain Language

The paper is a randomized study of Oxytocin.

The abstract goes on to report its results in about 11 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (American journal of obstetrics & gynecology MFM), a journal based in United States.

More context: the Oxytocin compound page, all human trials.

Our Notes on the Compound

Oxytocin: A peptide hormone with established obstetric medical uses and a less settled role in research on behavior, sexual function and appetite.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.